COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave
10.1136/ejhpharm-2021-002765
April 13, 2021
Open access
Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19
10.1136/ejhpharm-2020-002667
April 8, 2021
Tobramycin and vestibulotoxicity: retrospective analysis of four cases
10.1136/ejhpharm-2020-002588
March 22, 2021
SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces
10.1136/ejhpharm-2021-002692
February 8, 2021
An unusual case of piperacillin-tazobactam-induced fever, eosinophilia, thrombocytopenia and liver damage
10.1136/ejhpharm-2020-002575
February 8, 2021
Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
10.1136/ejhpharm-2021-002694
February 4, 2021
Is sitagliptin effective for the treatment of COVID-19?
10.1136/ejhpharm-2021-002702
January 27, 2021
Web searches for anxiolytic drugs during the COVID-19 outbreak in the USA
10.1136/ejhpharm-2020-002671
January 27, 2021
Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
10.1136/ejhpharm-2021-002680
January 20, 2021
Patient prioritisation for hospital pharmacy services: current approaches in the UK
10.1136/ejhpharm-2020-002365
December 1, 2020